Jun 08, 2021 4:30pm EDT Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
May 17, 2021 7:00am EDT Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 10, 2021 6:30am EDT Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 03, 2021 6:00am EDT Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
Mar 22, 2021 7:00am EDT Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations
Feb 16, 2021 8:10am EST Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update
Feb 03, 2021 6:30am EST Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting
Feb 01, 2021 6:30am EST Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates
Jan 25, 2021 6:30am EST Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080
